Osteoporosis: Therapeutic Options

Open access


The definition of osteoporosis was originally formulated at a conference of the World Health Organization (WHO) in 1993 as ‘a systemic skeletal disease characterized by decreased bone mass and altered micro-architecture of bone tissue, leading to enhanced bone fragility and risk of fractures’. Osteoporosis is characterized by low bone mineral density (BMD) and loss of the structural and bio-mechanical properties that are required to maintain bone homeostasis. This review aims to address the currently available options in prevention and treatment of osteoporosis. Management of osteoporosis includes non-pharmacological treatment - diet rich of calcium and vitamin D, healthy lifestyle, proper exercise plan, and pharmacological therapy. Combination of non-pharmacological and pharmacological treatment options have to be considered for prevention of osteoporosis and minimization of the risk of fractures. Given the heterogeneity of osteoporosis syndrome and lack of significant number of comparative studies, the choice of a pharmacological agents should be individualized.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Sambrook P Cooper C. Osteoporosis. Lancet 2006; 367 (9527):2010-18.

  • 2. Cheung AM Detsky AS. Osteoporosis and fractures: missing the bridge. JAMA 2008; 299:1468-70.

  • 3. Becker DJ Kilgore ML Morrisey MA. The societal burden of osteoporosis. Curr Rheumatol Rep 2010; 12:186.

  • 4. Pankova S Vasileva L Petkova V. A review of current treatment options for osteoporosis in Bulgaria. World Journal of Pharmacy and Pharmaceutical Sciences 2015;4(5):1-12.

  • 5. Sanders S Geraci SA. Osteoporosis in postmenopausal women: considerations in prevention and treatment: (women’s health series). South Med J 2013;106:698-706.

  • 6. Genazzani AR Gambacciani M Schneider HPG Christiansen C. Postmenopausal osteoporosis: therapeutic options. Climacteric 2005;8:99-109.

  • 7. Rachner T Khosla S Hofbauer A.Osteoporosis: now and the future. The Lancet 2011;377 (9773):1276-87.

  • 8. Panday K Gona A Humphrey M. Medicationinduced osteoporosis: screening and treatment strategies. Therapeutic Advances in Musculoskeletal Disease 2014;6(5):185-202.

  • 9. Deutschmann HA Weger M Weger W. Search for occult secondary osteoporosis: impact of identified possible risk factors on bone mineral density. J Intern Med 2002;252:389-97.

  • 10. Mazziotti G Canalis E Giustina A. Drug-induced osteoporosis: mechanisms and clinical Iimplications. Amer J Med 2010;123(10):877-84.

  • 11. van Staa T Leufkens HG Abenhain L. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.

  • 12. Borissova A-M Rashkov R Boyanov M Shinkov A Popivanov P Temelkova N Vlahov J Gavrailova M. Risk factors for osteoporosis and 10-year absolute fracture risk in a national representative sample of Bulgarian women aged 50 years and older. Endokrinologya 2011;16 (1):4-18 (in Bulgarian).

  • 13. Reginster JY Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006;38:4-9.

  • 14. Cummings R Melton J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;39:1761-7.

  • 15. Shuit SC Van Der Klift M Weel AE. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone 2004;34:195-202.

  • 16. Waugh EJ Lam MA Hawker GA. Risk factors for low bone mass in healthy 40-60 year old women: a systematic review of the literature. Osteoporos Int 2009;20:1-21.

  • 17. Cummings-Vaughn L Grammack J. Falls osteoporosis and hip fractures. Med Clin North Amer 2011;95(3):495-506.

  • 18. Cavalli L Brandi ML. Age- and gender-related macro- and micro-architecture changes in bone structure and implications for treatment. Int J Clin Rheumatol 2011;6:359-69.

  • 19. Coin A Perissinotto E Enzi G. Predictors of low bone mineral density in the elderly: role of dietary intake nutritional status and sarcopenia. Eur J Clin Nutr 2008;23:802-9.

  • 20. Seibel MJ Robins SP Bilezikian JP. Dynamics of bone and cartilage metabolism. San Diego: Academic Press; 2006:345-60.

  • 21. Holick MF Binkley NC Bischoff-Ferrari HA Gordon CM Hanley DA Heaney RP. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 2012;97:1153-8.

  • 22. Kanis JA Johansson H Johnell O. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005;16:737-42.

  • 23. Hallstrom H Wolk A Glynn A Michaëlsson K. Coffee tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women. Osteoporos Int 2006;17(7):1055-64.

  • 24. Kanis JA Johnell O Oden O. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2006;16: 155-62.

  • 25. Kasnakova P Chaushev G Blazhev D. Sports and physical activity in the prevention of osteoporosis in women working in the Medical College at the Medical University Plovdiv. Sport y nauka. Special edition. Proceedings of the fifth International Congress of “Sports Stress Adaptation” and “Olympic sports and sports for everyone”; Sofia 2010:373-4 (Bulgarian).

  • 26. Kasnakova P Velikov Y. Methodology of complex rehabilitation in cases of disk nemiation. Trakia Journal of Sciences 2012;10 (3):185-7.

  • 27. Kasnakova P Krushkova P Kostov S Slavcheva N. Importance of sports and aerobic exercise for prevention of obesity among children and adolescents. Proceeding book VI International Scientific Congress “Olympic Sport and Sport for All” & VI International Scientific Congress “Sport Stress Adaptation”; 2012 May 17-19; Sofi a. p. 479-81.

  • 28. Krushkova P. Kasnakova P. The role of sports and physical activity in the complex therapy for diabetes treatment. Proceeding book VI International Scientifi c Congress “Olympic Sport and Sport for All” & VI International Scientifi c Congress “Sport Stress Adaptation”; 2012 May 17-19; Sofi a. p. 481-4.

  • 29. Raisz LG. Pathogenesis of osteoporosis: concepts conflicts and prospects. J Clin Invest 2005;115: 3318-25.

  • 30. Gallagher J. Advances in bone biology and new treatments for bone loss. Maturitas 2008;60(1):65-9.

  • 31. Lewiecki EM Watts NE McClung MR.World Health Organization (WHO) Assessment of fracture risk and application to screening for postmenopausal osteoporosis report of a WHO study group WHO technical report series n 843 WHO Geneve Suisse 19941-29 Official position of the International society for chnical densitometry J Clin Endocnnol Metab 2004;89:3651-5.

  • 32. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-36.

  • 33. Tremollieres M. Ribot K. Bone mineral density and prediction of non-osteoporotic disease. Maturitas 2010;65(4):348-51.

  • 34. Mu H Bai YH Wang ST Zhu ZM Zhang YW. Research on antioxidant effects and estrogenic effect of Formononetin from Trifolium pratense (red clover). Phytomedicine 2009;16(4):314-9.

  • 35. Tang BM Eslick GD Newson C. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older a meta analyse. Lancet 2007;370:657-66.

  • 36. Mithal A Wahl DA Bonjour J. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 2009;20(11):1807-20.

  • 37. Bikle D. Vitamin D and bone. Curr Osteoporos Rep 2012;10(2):151-9.

  • 38. Russell R. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006;1068:367-401.

  • 39. Kimmel B. Mechanism of action pharmacokinetics and pharmacodynamic profi le and clinical application of nitrogen containing bisphosphonates. J Dent Res 2007;86(11):1022-33.

  • 40. van Beek E Cohen L Leroy I Ebetino F Löwik C Papapoulos S. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003;33(5):805-11.

  • 41. Cummings SR San Martin J McClung MR. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.

  • 42. Krassas GE Papadopoulou P. Oestrogen action on bone cells. J Musculoskelet Neuronal Interact 2001;2(2):143-51.

  • 43. Cauley JA Robbins J Chen Z. Women’s Health Initiative (WHI) investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomised trial. JAMA 2003;290:1729-38.

  • 44. Ascott-Evans B Sonnendecker E De Villiers T. Hormone therapy in postmenopausal osteoporosis. JEMDSA 2008;13:8-12.

  • 45. Tuck SP Francis RM. Testosterone bone and osteoporosis. Front Horm Res 2009;37:123-32.

  • 46. Chesnut CH Silverman S Andriano K. A randomised trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the PROOF study. Am J Med 2000;109:267-76.

  • 47. Rey JRC Cervino EV Rentero ML. Raloxifene: mechanism of action effects on bone tissue and applicability in clinical traumatology practice. Open Orthop J 2009;3:14-21.

  • 48. Sacco SM Horcajada MN Offord E. Phytonutrients for bone health during ageing. Br J Clin Pharmacol 2013;75(3):697-707.

  • 49. Cranney A Papaioannou A Zytaruk N. Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ 2006;175:52-9.

  • 50. European Medicines Agency. PRAC recommends suspending use of Protelos / Osseor (strontium ranelate) Recommendation by PRAC to be considered by CHMP for fi nal opinion. Press release 10 January 2014; p.1-2.

Journal information
Impact Factor

CiteScore 2018: 0.587

SCImago Journal Rank (SJR) 2018: 0.311

Cited By
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 623 363 23
PDF Downloads 336 195 29